Ence Chuck 4
4 · RELMADA THERAPEUTICS, INC. · Filed Jan 31, 2024
Insider Transaction Report
Form 4
Ence Chuck
CAO and COO
Transactions
- Purchase
Common Stock
2024-01-30$3.87/sh+14,500$56,053→ 25,300 total - Purchase
Common Stock
2024-01-29$3.65/sh+10,800$39,438→ 10,800 total - Purchase
Common Stock
2024-01-31$4.05/sh+13,670$55,429→ 38,970 total
Footnotes (4)
- [F1]The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- [F2]Purchase prices range from $3.585 to $3.73 per share, inclusive.
- [F3]Purchase prices range from $3.755 to $3.99 per share, inclusive.
- [F4]Purchase prices range from $3.93 to $4.17 per share, inclusive.